Oral absorption of peptides and nanoparticles across the human intestine: Opportunities, limitations and studies in human tissues

被引:367
作者
Lundquist, P. [1 ]
Artursson, P. [1 ]
机构
[1] Uppsala Univ, Dept Pharm, Box 580, SE-75237 Uppsala, Sweden
基金
瑞典研究理事会;
关键词
Oral drug delivery; Peptide drugs; Nanoparticles; Ussing chamber; Peptide permeability; Bioavailability; Human intestinal tissue; Human Protein Atla; Transcytosis; Transepithelial transport; HUMAN GASTROINTESTINAL-TRACT; SOLID LIPID NANOPARTICLES; TIGHT-JUNCTION PROTEINS; NEONATAL FC-RECEPTOR; EPITHELIAL M-CELLS; IN-VITRO MODEL; DRUG ABSORPTION; CHOLERA-TOXIN; BARRIER DYSFUNCTION; PEYERS-PATCHES;
D O I
10.1016/j.addr.2016.07.007
中图分类号
R9 [药学];
学科分类号
100702 [药剂学];
摘要
In this contribution, we review the molecular and physiological barriers to oral delivery of peptides and nanoparticles. We discuss the opportunities and predictivity of various in vitro systems with special emphasis on human intestine in Ussing chambers. First, the molecular constraints to peptide absorption are discussed. Then the physiological barriers to peptide delivery are examined. These include the gastric and intestinal environment, the mucus barrier, tight junctions between epithelial cells, the enterocytes of the intestinal epithelium, and the subepithelial tissue. Recent data from human proteome studies are used to provide information about the protein expression profiles of the different physiological barriers to peptide and nanoparticle absorption. Strategies that have been employed to increase peptide absorption across each of the barriers are discussed. Special consideration is given to attempts at utilizing endogenous transcytotic pathways. To reliably translate in vitro data on peptide or nanoparticle permeability to the in vivo situation in a human subject, the in vitro experimental system needs to realistically capture the central aspects of the mentioned barriers. Therefore, characteristics of common in vitro cell culture systems are discussed and compared to those of human intestinal tissues. Attempts to use the cell and tissue models for in vitro-in vivo extrapolation are reviewed. (C) 2016 The Authors. Published by Elsevier B.V.
引用
收藏
页码:256 / 276
页数:21
相关论文
共 270 条
[1]
Current status of selected oral peptide technologies in advanced preclinical development and in clinical trials [J].
Aguirre, T. A. S. ;
Teijeiro-Osorio, D. ;
Rosa, M. ;
Coulter, I. S. ;
Alonso, M. J. ;
Brayden, D. J. .
ADVANCED DRUG DELIVERY REVIEWS, 2016, 106 :223-241
[2]
In vitro and in vivo preclinical evaluation of a minisphere emulsion-based formulation (SmPill®) of salmon calcitonin [J].
Aguirre, Tanira A. S. ;
Rosa, Monica ;
Coulter, Ivan S. ;
Brayden, David J. .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2015, 79 :102-111
[3]
How common is vitamin B-12 deficiency? [J].
Allen, Lindsay H. .
AMERICAN JOURNAL OF CLINICAL NUTRITION, 2009, 89 (02) :693S-696S
[4]
Gastric intrinsic factor: The gastric and small intestinal stages of cobalamin absorption. A personal journey [J].
Alpers, David H. ;
Russell-Jones, Greg .
BIOCHIMIE, 2013, 95 (05) :989-994
[5]
Calcium and pH-dependent packing and release of the gel-forming MUC2 mucin [J].
Ambort, Daniel ;
Johansson, Malin E. V. ;
Gustafsson, Jenny K. ;
Nilsson, Harriet E. ;
Ermund, Anna ;
Johansson, Bengt R. ;
Koeck, Philip J. B. ;
Hebert, Hans ;
Hansson, Gunnar C. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2012, 109 (15) :5645-5650
[6]
[Anonymous], BREFELDIN A INHIBITS
[7]
[Anonymous], ACTA PHYSL
[8]
[Anonymous], 2006, Physiology of the Gastrointestinal Tract
[9]
[Anonymous], BIOCHIMIE
[10]
[Anonymous], P NATL ACAD SCI